Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
TripGift Launches Its Next-Generation Global Travel Value Platform8.9.2026 14:30:00 CEST | Press release
The 103-currency platform brings together global travel gift cards, rewards, incentives, programmable promotional vouchers and travel redemption across more than 180 countries. NEW YORK CITY, NY / ACCESS Newswire / September 8, 2026 / TripGift, the multi-award-winning global Travel Value Platform, today announced the launch of its next-generation platform, expanding how organizations can integrate travel value into customer, partner and employee programs. Building on TripGift's established global travel gifting and redemption capabilities, the platform brings together its eight proprietary travel gift brands, Travel Value API, Purpose-Bound Promotional Vouchers and travel redemption platform. TripGift's market-leading platform enables travel gift cards to be purchased in 103 currencies and redeemed across more than 180 countries, with access to 2.9 million+ travel and lifestyle booking options, including 2.8 million accommodations, 600 airlines, 30,000 mobility locations, 50,000 tours
A New Force in the Surf Park Economy8.9.2026 13:00:00 CEST | Press release
AWM and China Tourism Group launch Eastern Swell Dynamics SOLANA BEACH, CA / ACCESS Newswire / September 8, 2026 / American Wave Machines is pleased to announce the formation of Eastern Swell Dynamics, a new joint venture established with China Tourism Group to support the growth of PerfectSwell® surf pools across China. The new company will serve as the official licensed platform for PerfectSwell® projects in the region, bringing together AWM's proven surf technology with CTG's deep tourism infrastructure, development capabilities, market access and longstanding presence across Greater China. Riyue Bay Surf Resort powered by PerfectSwell® surf technology China Tourism Group is one of the most significant tourism enterprises in China, with a history dating back more than a century and a business network spanning mainland China, and international markets. Its platform includes travel services, scenic destinations, hotels, duty free retail, tourism transportation, real estate, cultural t
OMP Asia Conferences to Showcase How Industry Leaders Kraft Heinz, Mars, Medac, And Nestlé Approach AI-Powered Supply Chain Planning At "Decision Velocity"8.9.2026 11:35:00 CEST | Press release
Events also feature acclaimed keynote speakers Andrea Iorio, author of "Between You and AI" and former Chief Digital Officer at L'Oréal, and Junjun Gao, a leading voice on supply chain digital transformation in China. SINGAPORE, SG / ACCESS Newswire / September 8, 2026 / OMP, a leading provider of supply chain planning solutions, returns to Asia with two OMP Conferences: Singapore on October 15 and Shanghai on October 20, 2026. Under the theme "Decision velocity," the events bring together supply chain leaders, practitioners, and technology experts to explore how AI-enabled planning helps organizations turn insights into action, respond faster to disruption, and advance toward autonomous planning. The program features customer sessions in Singapore with Nestlé, Kraft Heinz, and Medac, in partnership with PwC, and in Shanghai with Dow and Mars. They will share how they are advancing supply chain planning, strengthening capabilities, and using AI and data to make faster, better decisions
Flow Technology partners with BW Forsyth Partners to Meet Growing Demand for Biopharmaceutical Manufacturing7.9.2026 10:00:00 CEST | Press release
Investment supports Flow Technology's ability to help pharmaceutical and biotechnology manufacturers expand production and navigate increasingly complex manufacturing requirements CHARLEVILLE, IRELAND / ACCESS Newswire / September 7, 2026 / Flow Technology, a provider of engineered process systems and skid integration solutions serving the global life sciences industry, announced a partnership with BW Forsyth Partners that will support the company's continued expansion in the United States and Europe, and enhance its ability to serve the evolving needs of global pharmaceutical and biotechnology manufacturers. The partnership comes as pharmaceutical and biotechnology companies invest heavily in production capacity, advanced manufacturing technologies and domestic supply chains. Flow Technology's expertise in downstream purification, filtration and chromatography systems positions the company to support the increasingly sophisticated process infrastructure required to manufacture next-ge
LiberNovo Showcases Dynamic Ergonomic Seating at IFA 2026 and Supports Special Olympics New York4.9.2026 18:30:00 CEST | Press release
Maxis Series Brings More Space, Support and Choice to Big & Tall Users BERLIN, DE / ACCESS Newswire / September 4, 2026 / LiberNovo is exhibiting at IFA 2026 from September 4 to 8 at Messe Berlin, presenting its dynamic ergonomic seating range at Hall 7, Stand 7.2a-105. The Maxis Series leads the stand, alongside the LiberNovo Omni Pro and Omni SE. LiberNovo Omni Pro has also earned nominations in two IFA Innovation Awards categories: Best in Design and Best in Tech for Good & Accessibility. IFA is a leading event for consumer technology and home appliances, connecting brands, retailers, buyers and media. Its 2026 theme, "The future is now," highlights technology reshaping everyday life. As hybrid work, gaming and content creation extend sitting time, LiberNovo presents seating as an active support system rather than a static object. Maxis Series: Built for Bigger Builds Maxis was designed for taller, broader and heavier users rather than scaled up from a standard chair. Its 52 cm (20.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom